[ad_1]
Article content material
SAINT LAURENT, Quebec, Aug. 07, 2023 (GLOBE NEWSWIRE) — IntelGenx Applied sciences Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a frontrunner in pharmaceutical movies, at this time introduced that it’s going to launch its second quarter 2023 monetary outcomes after market shut on Monday, August 14, 2023.
An accompanying convention name might be hosted by Dwight Gorham, Chief Govt Officer, Andre Godin, President and Chief Monetary Officer, and Dr. Horst G. Zerbe, Chairman, to debate the outcomes and supply a enterprise updateDetails of the convention name and webcast are beneath:
Article content material
Second Quarter 2023 Outcomes Convention Name Particulars:
| Date: | Monday, August 14, 2023 |
| Time: | 4:30 p.m. ET |
| Stay Name: | 1-888-506-0062 (Canada and america) |
| 1-973-528-0011 (Worldwide) | |
| Entry Code: | 570916 |
The decision may even be broadcast stay and archived on the Firm’s web site at www.intelgenx.com underneath “Webcasts” within the Traders part.
About IntelGenx
IntelGenx is a number one drug supply firm centered on the event and manufacturing of pharmaceutical movies.
IntelGenx’s superior movie applied sciences, together with VersaFilm®, DisinteQ™, VetaFilm® and transdermal VevaDerm™, enable for subsequent era pharmaceutical merchandise that handle unmet medical wants. IntelGenx’s revolutionary product pipeline presents important advantages to sufferers and physicians for a lot of therapeutic circumstances.
IntelGenx’s extremely expert group offers complete prescribed drugs companies to pharmaceutical companions, together with R&D, analytical methodology improvement, scientific monitoring, IP and regulatory companies. IntelGenx’s state-of-the-art manufacturing facility presents full service by offering lab-scale to pilot- and commercial-scale manufacturing. For extra info, go to www.intelgenx.com.
Article content material
Ahead-Trying Data and Statements
This doc might include forward-looking details about IntelGenx’s working outcomes and enterprise prospects that contain substantial dangers and uncertainties. Statements that aren’t purely historic are forward-looking statements throughout the that means of Part 21E of the Securities Change Act of 1934, as amended, and Part 27A of the Securities Act of 1933, as amended. These statements embrace, however should not restricted to, statements about IntelGenx’s plans, targets, expectations, methods, intentions or different characterizations of future occasions or circumstances and are usually recognized by the phrases “might,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “might,” “would,” and related expressions. All ahead wanting statements are expressly certified of their entirety by this cautionary assertion. As a result of these forward-looking statements are topic to various dangers and uncertainties, IntelGenx’s precise outcomes might differ materially from these expressed or implied by these forward-looking statements. Elements that might trigger or contribute to such variations embrace, however should not restricted to, these mentioned underneath the heading “Danger Elements” in IntelGenx’s annual report on Type 10-Okay, filed with america Securities and Change Fee and out there at www.sec.gov, and in addition filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to replace any such forward-looking statements.
Supply: IntelGenx Applied sciences Corp.
For IntelGenx:
Stephen Kilmer
Investor Relations
(647) 872-4849
stephen@kilmerlucas.com
Or
Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com
[ad_2]
Source link
